Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges

被引：8

作者：

D'Aiello, Angelica ^{[1
,6
]}

Stiles, Brendon ^{[2
]}

Ohri, Nitin ^{[3
]}

Levy, Benjamin ^{[4
]}

Cohen, Perry ^{[5
]}

Halmos, Balazs ^{[1
,6
]}

机构：

[1] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, Bronx, NY USA

[2] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Div Thorac Surg & Surg Oncol, Bronx, NY USA

[3] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Radiat Oncol, Bronx, NY USA

[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA

[5] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Pathol, Div Anat & Clin Pathol, Bronx, NY USA

[6] Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USA

来源：

CLINICAL LUNG CANCER | 2024年 / 25卷 / 03期

关键词：

Adjuvant; Immunotherapy; Lung cancer; NSCLC; Neoadjuvant; NEOADJUVANT ATEZOLIZUMAB; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; PLUS CHEMOTHERAPY; OPEN-LABEL; RADIOTHERAPY; PEMBROLIZUMAB; DURVALUMAB; SURGERY; NSCLC;

D O I：

10.1016/j.cllc.2024.02.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting. As more results read out from ongoing per ioperative clinical tr ials, navigating treatment options will likely become increasingly complex for the practicing oncologist. In this paper, we distill key outcomes from major perioperative trials and highlight current knowledge gaps. In addition, we provide practical considerations for incorporating perioperative immunotherapy into the clinical management of operable NSCLC.

引用

页码：197 / 214

页数：18

共 77 条

[1]

Aigner C, 2023, J CLIN ONCOL, V41

[2] US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer [J].

Akinboro, Oladimeji ;

Drezner, Nicole ;

Amatya, Anup ;

Runyan, Jin ;

Fourie-Zirkelbach, Jeanne ;

Zhao, Miao ;

Bi, Youwei ;

Korsah, Kwadwo ;

Mixter, Bronwyn ;

Tang, Shenghui ;

Larkins, Erin ;

Pazdur, Richard ;

Beaver, Julia A. A. ;

Singh, Harpreet .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17) :3249-+

[3] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].

Altorki, Nasser K. ;

McGraw, Timothy E. ;

Borczuk, Alain C. ;

Saxena, Ashish ;

Port, Jeffrey L. ;

Stiles, Brendon M. ;

Lee, Benjamin E. ;

Sanfilippo, Nicholas J. ;

Scheff, Ronald J. ;

Pua, Bradley B. ;

Gruden, James F. ;

Christos, Paul J. ;

Spinelli, Cathy ;

Gakuria, Joyce ;

Uppal, Manik ;

Binder, Bhavneet ;

Elemento, Olivier ;

Ballman, Karla, V ;

Formenti, Silvia C. .

LANCET ONCOLOGY, 2021, 22 (06) :824-835

[4]

[Anonymous], 2020, FDA approves pembrolizumabfor adults and children with TMB-H solid tumors

[5]

[Anonymous], NCCN CLIN PRACTICE G

[6] Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity [J].

Bakos, Orneala ;

Lawson, Christine ;

Rouleau, Samuel ;

Tai, Lee-Hwa .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[7] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial [J].

Besse, B. ;

Adam, J. ;

Cozic, N. ;

Chaput-Gras, N. ;

Planchard, D. ;

Mezquita, L. ;

Remon Masip, J. ;

Lavaud, P. ;

Naltet, C. ;

Gazzah, A. ;

de Montpreville, V. Thomas ;

Ghigna, M. -R. ;

Mussot, S. ;

Fadel, E. ;

Mabille, L. ;

Duchemann, B. ;

Barlesi, F. ;

Soria, J-C. ;

Caramella, C. ;

Mercier, O. .

ANNALS OF ONCOLOGY, 2020, 31 :S794-S795

[8] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Tierney, Jayne F. ;

Auperin, Anne ;

Le Pechoux, Cecile ;

Le Chevalier, Thierry ;

Pignon, Jean-Pierre .

LANCET, 2014, 383 (9928) :1561-1571

[9] Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy [J].

Casarrubios, Marta ;

Provencio, Mariano ;

Nadal, Ernest ;

Insa, Amelia ;

Garcia-Campelo, Maria Del Rosario ;

Lazaro-Quintela, Martin ;

Domine, Manuel ;

Majem, Margarita ;

Rodriguez-Abreu, Delvys ;

Martinez-Marti, Alex ;

Carpeno, Javier De Castro ;

Cobo, Manuel ;

Vivanco, Guillermo Lopez ;

Del Barco, Edel ;

Bernabe, Reyes ;

Vinolas, Nuria ;

Aranda, Isidoro Barneto ;

Massuti, Bartomeu ;

Sierra-Rodero, Belen ;

Martinez-Toledo, Cristina ;

Fernandez-Miranda, Ismael ;

Serna-Blanco, Roberto ;

Romero, Atocha ;

Calvo, Virginia ;

Cruz-Bermudez, Alberto .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)

[10] CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC [J].

Cascone, T. ;

Awad, M. M. ;

Spicer, J. D. ;

He, J. ;

Lu, S. ;

Sepesi, B. ;

Tanaka, F. ;

Taube, J. M. ;

Cornelissen, R. ;

Havel, L. ;

Kuzdzal, J. ;

Petruzelka, L. B. ;

Wu, L. ;

Pujol, J. L. ;

Ito, H. ;

Erdmann, C. Coronado ;

Sathyanarayana, P. ;

Meadows-Shropshire, S. ;

Pulla, M. Provencio .

ANNALS OF ONCOLOGY, 2023, 34 :S1295-S1295

← 1 2 3 4 5 6 7 8 →